April 30, 2024

Grifols successfully completes its EUR 1 billion private placement of senior secured notes

Download PDF
  • The transaction has closed with an annual coupon of 7.5% and maturity in May 2030.
  • The Senior Secured Notes have already been issued and the proceeds have been received, at a purchase price of 98.50% of the principal amount.
  • The proceeds will be used to redeem Grifols' Senior Unsecured Notes due in May 2025.

Barcelona, Spain – April, 30, 2024 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, announced today the successful completion of its private offering of EUR 1 billion of 7.5% senior secured notes due May 2030.

The company announced the signing of the private offering on April 23, 2024.

The notes have already been issued and the proceeds have been received, at a purchase price of 98.50% of the principal amount of the Notes, and hence, the private placement has been closed successfully.

The full proceeds from this transaction will be used to redeem Grifols' Senior Unsecured Notes due in May 2025.

The closing of this transaction demonstrates the confidence of the financial markets in Grifols' solid business and operational resilience. It also represents an important step forward in addressing the 2025 maturities and strengthens the Company’s long-term financial framework.

Grifols has been advised by Osborne Clarke and Proskauer Rose LLP. Deutsche Bank has acted as placement agent to the Company.